Edwin Elmhirst
Data Journalist
![](/-/media/staff-photos/edwin-elmhirst-round.png?rev=d059b21ca6a643ce9dc6de71ca45dcdd)
Latest From Edwin Elmhirst
Titans Of Pharma: J&J Back On Top For CEO Remuneration
J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.
Obesity Rules Large-Cap Stocks In First Half Of 2024
Lilly and Novo Nordisk were top performers among large-cap pharma stocks, while the stock prices of Bristol Myers and Gilead declined the most.
Titans Of Pharma: J&J Back On Top For CEO Remuneration
J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.
Analysis: Novo And Lilly Make Their Money Work
Pharma groups must decide how best to invest their cash to generate the biggest returns, and while huge sums can be made with luck and good judgement, strategic missteps can have far-reaching consequences.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.